📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Wanbury Launches Anaesthetic API Production; Targets ₹100 Cr+ Incremental Revenue in FY27
Wanbury Limited has commenced commercial production of a high-potent anaesthetic API at its Tanuku facility in Andhra Pradesh. This move is expected to generate incremental revenues of approximately ₹18 crore in Q4 FY26 and over ₹100 crore in FY 2026-27. The company is also expanding its capacity with a multi-purpose intermediate block scheduled for completion by March 2026. This expansion aims to capture a share of the global market for these new APIs, which is currently valued at over ₹5,000 crore.
Key Highlights
Commenced commercial production of a key anaesthetic API at the state-of-the-art Tanuku facility.
Projected incremental revenue of over ₹100 crore in FY 2026-27 from the new API production.
Expected immediate revenue contribution of approximately ₹18 crore in Q4 FY 2025-26.
On track to launch four additional high-value APIs (Antidiabetic, Anticoagulant, etc.) by March 2026.
Targets a global market opportunity for these molecules valued at over ₹5,000 crore.
💼 Action for Investors
Investors should track the company's ability to scale production and meet the ₹18 crore revenue target in Q4 FY26 as a sign of execution capability. The successful launch of the additional four APIs in March 2026 could be a further re-rating trigger for the stock.